JW (Cayman) Therapeutics Co. Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JWCTF research report →
Price Chart
About the company
JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions. Its core mission is to combat both hematological cancers (blood cancers) and various solid tumors.
- CEO
- Tian Feng
- IPO
- 2021
- Employees
- 314
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on JWCTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $84.22M
- P/E
- -3.06
- PEG
- -0.06
- P/S
- 3.56
- P/B
- 2.25
- EV/EBITDA
- -4.41
- Div Yield
- 0.00%
- Gross Margin
- 39.80%
- Op Margin
- -95.03%
- Net Margin
- -116.75%
- ROE
- -66.16%
- ROIC
- -38.41%
Latest fiscal year · YoY change
- Revenue
- $276.33M+74.7%
- Gross Profit
- $118.92M+53.8%
- Op Income
- $-241,728,741
- Net Income
- $-540,962,213+8.4%
- EPS
- $-1.33+7.0%
- OCF Growth
- +77.0%
- FCF Growth
- +77.5%
- 52W High
- $0.53
- 52W Low
- $0.20
- 50D MA
- $0.20
- 200D MA
- $0.26
- Beta
- 1.90
- RSI (14)
- 0
- Avg Volume
- 1
No earnings-call transcripts are available for JWCTF yet.
- Free Float
- 76.6%
- Shares Outstanding
- 416.47M
- Float Shares
- 318.86M
Our JWCTF coverage
Recent articles, reports, and earnings notes.
No research on JWCTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JWCTF report →